Dr Lalchandani Labs Limited has announced board approval for a rights issue worth ₹433.31 lakhs and scheduled a follow-up board meeting to finalize the terms. The healthcare sector company plans to raise funds through the issuance of equity shares with a face value of ₹10 each to eligible shareholders.

Initial Board Meeting Outcomes

The board of directors convened and held its meeting on December 15, 2025, from 4:00 PM to 5:00 PM. The meeting approved the fundraising initiative through rights issue mechanism. This decision comes after the company had initially scheduled the board meeting for December 9, 2025, which was subsequently deferred to December 15, 2025.

Upcoming Board Meeting for Terms Fixation

Following the initial approval, the company has scheduled another board meeting on December 22, 2025, to finalize the specific terms of the rights issue. The upcoming meeting will address critical parameters including:

Rights Issue Framework

The company has outlined the key parameters of the proposed rights issue based on the initial board approval:

Regulatory Compliance and Next Steps

The rights issue intimation has been provided pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The rights issue remains subject to receipt of statutory and regulatory approvals in accordance with the amended SEBI (Issue of Capital and Disclosure Requirements) Amendment Regulations, 2025 and other applicable laws.

The December 22 board meeting will determine the final terms including issue price, rights entitlement ratio, record date, timing, and terms of payment in accordance with applicable laws, subject to receipt of necessary approvals. The company has indicated that all requisite regulatory approvals will be obtained as required under the framework.

Dr Lalchandani Labs Limited , a prominent player in the healthcare sector, has announced significant corporate developments following a board meeting held on September 05, 2025. The company has made key decisions aimed at strengthening its governance structure and preparing for future growth.

New Independent Director Appointment

The board has approved the appointment of Mr. Mohan Lal Gandhi as a Non-Executive Independent Director for a five-year term, commencing from September 05, 2025, to September 04, 2030. This appointment is subject to necessary approvals.

Mr. Gandhi brings a wealth of experience to the board. He is a distinguished medical professional, having completed his M.B.B.S. from the University College of Medical Sciences (UCMS), New Delhi, in 1975. His career includes training at Safdarjung Hospital and holding director positions in both private and public sector companies. Notably, Mr. Gandhi has also served as the President of the Chamber of Commerce for two years, demonstrating his leadership in the business community.

Beyond his professional achievements, Mr. Gandhi is known for his philanthropic efforts, particularly in supporting underprivileged communities through hospital and educational initiatives.

Increase in Authorized Capital

In a move that signals preparation for potential future expansion, Dr Lalchandani Labs has approved an increase in its authorized capital. The company's authorized capital will be raised from Rs. 4.50 crore to Rs. 11.00 crore, representing a substantial increase of Rs. 6.50 crore. This decision is also subject to requisite approvals.

Annual General Meeting and Auditor Appointments

The board has approved the company's 8th Annual Report and scheduled the 8th Annual General Meeting for September 30, 2025, to be held in New Delhi. In line with this, the company has announced that the Register of Members and Share Transfer Books will remain closed from September 24, 2025, to September 30, 2025 (both days inclusive) for the purpose of the AGM.

Additionally, Dr Lalchandani Labs has appointed M/s. Chauhan Pradeep & Associates as Secretarial Auditors for a five-year term, covering the financial years 2025-26 to 2029-30. The same firm has also been appointed as the scrutinizer for the upcoming AGM.

These developments reflect Dr Lalchandani Labs' commitment to robust corporate governance and strategic growth. The appointment of Mr. Gandhi as an Independent Director and the increase in authorized capital position the company for potential expansion and enhanced oversight in the coming years.